Search results
Results From The WOW.Com Content Network
Efforts to establish a medical cannabis program in Tennessee have failed in the Republican-dominated state legislature. Federal reclassification to Schedule 3 would, for the first time at the ...
After being proposed repeatedly since 1972, the U.S. Department of Justice initiated 2024 rulemaking to reschedule cannabis to Schedule III of the Controlled Substances Act. The majority of 2024 public comments supported descheduling, decriminalizing, or legalizing marijuana at the federal level. [1]
However, the move to reschedule the drug is largely due to the lower public health risks, federal scientists have said. The rescheduling of marijuana to a Schedule III drug would allow for further ...
The groups alleged that at least one high-level DEA official had communicated with opponents of marijuana rescheduling, helping them improve their chances of being chosen as a participant in the ...
The Drug Enforcement Administration initiated a 2024 policy review to potentially reschedule marijuana as a Schedule III drug, amounting to "the agency's biggest policy change in more than 50 years". [4] Some hiring and retention policies in federal employment and the armed forces evolved during 2024.
The year 2022 began with several United States cannabis reform proposals pre-filed in 2021 for the upcoming year's legislative session. Among the remaining prohibitionist states, legalization of adult use in Delaware and Oklahoma was considered most likely, and Maryland, Ohio, Pennsylvania and Rhode Island somewhat less likely; medical cannabis in Mississippi was called likely at the beginning ...
In Tennessee, both medical and recreational uses of marijuana will remain illegal and the Food, Drug and Cosmetic Act will still prohibit selling marijuana across state lines.
Timeline of Gallup polls in US on legalizing marijuana. [1]In the United States, cannabis is legal in 39 of 50 states for medical use and 24 states for recreational use. At the federal level, cannabis is classified as a Schedule I drug under the Controlled Substances Act, determined to have a high potential for abuse and no accepted medical use, prohibiting its use for any purpose. [2]